Previous Pause Next
Home >> News Center >>
TGen, Karmanos Lead $6M Melanoma Project PDF Print E-mail
User Rating :  / 0
Thursday, 15 December 2011 05:55

NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute said today that it will partner with the Barbara Ann Karmanos Cancer Institute and several other partners in a $6 million study that will use genomics and other approaches to aid in the development of skin cancer therapies.

Funded by Stand up to Cancer (SU2C) and the Melanoma Research Alliance (MRA), the three-year SU2C-MRA Melanoma Dream Team Translational Cancer Research collaboration will seek to accelerate potential treatments for BRAF wild-type melanoma, which has few treatments.

TGen President and Research Director Jeffrey Trent, one of the project's leaders, will supervise genomic sequencing to support the project, TGen said.

"We hope to use this unique multi-stage clinical investigation to define new treatments that will produce benefits for metastatic melanoma patients, based on extensive genomic profiling," Patricia LoRusso, another project leader and director of the Eisenberg Center for Experimental Therapeutics at Karmanos, said in a statement. "We have great scientists and clinicians from across the nation who will join forces on this."

LoRusso will supervise patient selection, tissue sample handling, and clinical trials research on the project, which will involve around 150 patients.

Other collaborators on the project include Mayo Clinic; the Biodesign Institute at Arizona State University; the Van Andel Research Institute; Michigan State University; Scripps Research Institute; Sanford-Burnham Medical Research Institute; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; Johns Hopkins University; the University of California Santa Cruz; Scottsdale Healthcare; the National Cancer Institute; and the Queensland Institute for Medical Research.

"Our expertise in cell-based assays and proteomics hold promise for making new discoveries to advance our understanding of molecularly guided melanoma therapies and ultimately improve patient outcomes," said Deirdre Meldrum, director of the Biodesign Institute's Center for Biosignatures Discovery Automation.

Source: GenomeWeb

 
FairExcellent 

Add comment  |   Add to my library  |  Forward this article

login to leave comment

Collaboration, Projects, & Consortia

Indiana Clinical and Translational Science Institute HUB: A model for collaboration

TGen, Karmanos Lead $6M Melanoma Project

Sanford-Burnham Medical Research Institute and Pfizer Collaborate to Speed Drug Discovery

e2v aerospace and defense and Maxim Announce an Agreement to Extend the Product Life of Maxim Ceramic ICs

Syntaxin and Ipsen Ally to Develop Botulinum Toxin Therapeutics

BioAmber and LANXESS Partner for Renewable, Phthalate-free Plasticizers

Corgenix Partners with AXA Diagnostics on SkyLAB 752™ Automated Testing Platform

GeoVax and Vivalis Sign Deal for the Biomanufacture of MVA HIV Vaccine in EB66 Cells

EMD Serono and Fast Forward Commit $3 Million for Multiple Sclerosis

VisionGate Begins Collaborations to Evaluate 3-D Cell Analysis Test for Lung Cancer Screening

>> More in: Collaboration, Projects and Consortia

Featured Experts

Featured Laboratories

Grant & Funding Opportunities

Federally funded research & development centers employed more than 3,000 postdoctoral researchers

Federally-funded Research and Development Centers Spend $17.8 Billion in Fiscal Year 2011

NHGRI Unveils New-Look Genome Sequencing Program; Plans $416M in Funding

NYU to Study Genetics of Obesity-Related Cancers

Researchers Get NHGRI Funding to Study Effects of Alzheimer's Risk Testing

Venture Firms Pump $18M into Fledgling Arteaus Therapeutics

Servier and miRagen Sign $352M Deal for Cardiovascular miRNA Therapeutics

Tetraphase Awarded Initial $6M by NIAID to Develop Antibiotic Against Biothreats

Dermira Announces a $42m Series A Financing to Fund Therapeutic Advances in Dermatology

Salk Institute for Biological Studies to Accelerate Brain Research With $4.5 Million National Institutes of Health (NIH) Grant

>> More in: Grant & Funding Opportunities

Appointments

Sanofi (France) Taps David Meeker as New CEO of Genzyme Corporation

Drug Information Association Appoints Kaushik Desai as DIA India Director

Sentrx Announces Resignation of Charles T. Saldarini As CEO

EKR Therapeutics Announces Senior Management Change

Amgen Appoints Robert A. Bradway to the Company's Board of Directors

Anavex Life Sciences Corp. Appoints Dr. George Tidmarsh as Executive Director

Isis Biopolymer Appoints New President and CEO

RedHill Biopharma Appoints Key Opinion Leader Professor David Y. Graham from Baylor College of Medicine, Houston, Texas, as Lead Investigator for the US Pivotal Clinical Trial with RedHill's Crohn’s Drug – RHB-104

Apceth is Extending its Top Management: Prof. Ralf Huss Moves from Roche (RHHBY) to the Biotechnology Company apceth

BioIndustry Association Board Appointments

>> More in: Appointments

Recognitions

Journal names discovery that HIV treatment can prevent spread 'breakthrough of the year'

Abbott Laboratories's Absorb(TM) Bioresorbable Vascular Scaffold Honored with Wall Street Journal Technology Innovation Award

Chris Henney Receives 2011 Hall of Fame Award at Annual Biotech CEO Meeting at Laguna Beach

Scripps Florida Scientist Awarded $2.2 Million Grant To Study Hepatitis C

SAMHSA Awards Up To $25 Million To Expand Use Of Health Information Technology

Ablitech, Inc. Awarded $2 Million

The Michael J. Fox Foundation Awards AFFiRiS AG $1.5 Million for the Clinical Development of the First Parkinson's Disease Vaccine

SAMHSA Awards Grant To UCLA For Substance Abuse Prevention In Iraq

KGI Professor Awarded Patent For Stem-Cell Therapy Aiding Heart-attack Patients

Nobel Prize for chemistry 2011 goes to Israeli scientist Daniel Shechtman

>> More in: Recognitions